Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,306 | -9,796 | -5,377 | -2,775 | N/A |
| Depreciation Amortization | 2,720 | 798 | 773 | 965 | N/A |
| Accounts receivable | N/A | 7 | -7 | N/A | N/A |
| Other Working Capital | 598 | -359 | 299 | 255 | N/A |
| Other Operating Activity | 1,400 | 1,648 | 1,011 | 240 | 0 |
| Operating Cash Flow | $-8,589 | $-7,703 | $-3,301 | $-1,316 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -44 | -100 | -8 | N/A | N/A |
| Investing Cash Flow | $-44 | $-100 | $-8 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,491 | 935 | 225 | 1,304 | N/A |
| Common Stock Issued | 125 | 7,737 | 8,591 | 5 | N/A |
| Other Financing Activity | 5,720 | 0 | -50 | 132 | 0 |
| Financing Cash Flow | $8,335 | $8,672 | $8,766 | $1,441 | $N/A |
| Beginning Cash Position | 6,471 | 5,602 | 145 | 19 | N/A |
| End Cash Position | 6,174 | 6,471 | 5,602 | 145 | N/A |
| Net Cash Flow | $-297 | $870 | $5,457 | $126 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,589 | -7,703 | -3,301 | -1,316 | N/A |
| Capital Expenditure | -44 | -100 | -8 | N/A | N/A |
| Free Cash Flow | -8,633 | -7,803 | -3,309 | -1,316 | 0 |